156
Participants
Start Date
May 19, 2022
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2029
ELA026
Multiple doses of ELA026
RECRUITING
Columbia University, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Thomas Jefferson University, Philadelphia
ACTIVE_NOT_RECRUITING
MedStar Georgetown, Washington D.C.
RECRUITING
Johns Hopkins All Children's Hospital, St. Petersburg
RECRUITING
University of Alabama at Birmingham School of Medicine, Birmingham
RECRUITING
Texas Children's Hospital, Houston
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Huntsman Cancer Institute, Salt Lake City
ACTIVE_NOT_RECRUITING
Phoenix Children's Hospital, Phoenix
ACTIVE_NOT_RECRUITING
University of California, Los Angeles, Los Angeles
WITHDRAWN
Medizinische Universität Innsbruck, Innsbruck
COMPLETED
Medical University of Vienna, Vienna
COMPLETED
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan
WITHDRAWN
Bambino Gesu' Roma, Roma
ACTIVE_NOT_RECRUITING
Amsterdam UMC, Amsterdam
ACTIVE_NOT_RECRUITING
Erasmus UMC, Rotterdam
WITHDRAWN
Hospital 12 de Octubre, Madrid, Madrid
COMPLETED
Hospital Ramon y Cajal, Madrid
WITHDRAWN
Hospital La Fe Valencia, Valencia
ACTIVE_NOT_RECRUITING
University College London Hospitals, London
RECRUITING
Universitätsklinikum Jena, Jena
Lead Sponsor
Electra Therapeutics Inc.
INDUSTRY